Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
What's Your Reaction?
_id_803ca5ef-1be9-4d2b-936b-173127cf62d2_size900.jpg?#)
